Out-licensing

Dendritic cell (DC) generation and manipulation technology for the development of a cancer vaccine and rheumatoid arthritis (RA) therapeutics. Based on DC manipulating technology, Creagene is developing DC-based cancer vaccines against renal cell car

Manipulated dendritic cell based cancer vaccine induce memory immune responses against recurrence and metastasis resulting in long term effectiveness; CTP can transport attached bio-polymers like nucl

CreaVax RCC Inj. can induce a powerful active immunity in cancer patients by enhancing the body's natural tendency to defend itself against malignant tumors. It is completely free from side effects or toxicity since it is an autologous dendritic cell-based tumor vaccine. In the clinical study in RCC patients, 11% of RCC patients achieved partial response and 56% of RCC patients achieved stable disease based on RECIST criteria.  Median overall survival was 28.9 months which is more than two times of that of IL-2.  There were no dose limiting toxicity (DLT) and no NCI grade 3 or 4 toxicity. CreaVax RCC Inj. was approved from the Korea Food & Drug Administration as a new drug in October, 2007.

CTP was developed through modeling of the PTD (Protein Transduction Domain) in HIV-1 TAT protein. CTP can transport attached bio-polymers like nucleic acids or proteins into the cell with high permeation efficiency, 2 to 5 times better than PTD. Since NLS (nuclear localization signal) of the PTD has been modified so as not to transport substance into the nucleus, CTP can minimize gene damages caused by attached bio-polymers by keeping them in the cytoplasm not in the nucleus.  CTP shows much less cytotoxicity than other cell penetration peptides such as PTD or poly-Arg.  Especially, CTP shows the specific tropism to the liver and lymph node in mouse models.

Phase I/II

PCT Application

- Pharmaceutical Compositions Comprising Dendritic Cells for Immunotherapy of Autoimmune

- Disease and Treatement Mothods Using the same (PCT/KR02/00780),.China(028014502),   Japan(2002-584968).

- Cytoplasmic Transduction Peptides and Uses thereof  (PCT/KR03/00630)

-Novel Dendrtitic Cell-Specific Polynucleotides and Microarray Comprising the
Same (PCT/KR03/00631)

 

1. Overseas licensing opportunity

2. Seeking potential corporate partners

 

US7101844; US7138274